Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | CCNK | O75909 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16445330 | 1.00 | KDM4E (0.39) | KDM4EALDH1A1GAAALOX15IRAK4 | |
| SCHEMBL16444776 | 0.83 | HCAR3 (0.51) | — | |
| SCHEMBL16989761 | 0.83 | HCAR3 (0.51) | — | |
| SCHEMBL16444775 | 0.83 | HCAR3 (0.51) | — | |
| SCHEMBL16989779 | 0.83 | ALOX15 (0.39) | KDM4EALDH1A1ALOX15IRAK4 | |
| SCHEMBL16989777 | 0.83 | ALOX15 (0.39) | KDM4EALDH1A1ALOX15IRAK4 | |
| SCHEMBL16989781 | 0.80 | KDM4E (0.49) | KDM4EGAAALOX15 | |
| SCHEMBL16989782 | 0.80 | KDM4E (0.49) | KDM4EGAAALOX15 | |
| SCHEMBL8250121 | 0.79 | KDM4E (0.53) | KDM4EALDH1A1GAAALOX15IRAK4 | |
| SCHEMBL16444870 | 0.79 | KDM4E (0.46) | KDM4EALDH1A1GAAALOX15IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505749-B2 | Quinazolinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9340549-B2 | Oxazolidinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150225396-A1 | Quinazolinone Compounds and Derivatives Thereof | AMGEN INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225396-A1 | Quinazolinone Compounds and Derivatives Thereof | TNKS, TPI1, TNKS1BP1 | KDM4E 603/4885ALDH1A1 1715/4885GAA 249/4885 |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | TNKS1BP1, TNKS, TBKBP1 | KDM4E 1142/4885ALDH1A1 1646/4885GAA 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.